A biotech business has launched in Oxford in a bid to tackle one of the world’s rarest diseases.
SynaptixBio is working to develop a disease-modifying treatment for TUBB4a leukodystrophy, including H-ABC – a debilitating and potentially life-limiting neurodegenerative condition.
To continue reading please go to the article on Ability Today